WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody February 1, 2026
Alteogen Announces Exclusive License Agreement with Tesaro for the Development of a SQ Formulation of Dostarlimab Enabled by Hybrozyme™ Technology January 26, 2026
Infinitopes Expands Seed Financing to $35M to Accelerate Clinical Development of Precision Cancer Vaccine January 26, 2026
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class ADCs for Hard-to-Treat Cancers January 18, 2026
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro January 11, 2026
Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Gen Bispecific ADCs January 11, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications January 11, 2026
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies January 11, 2026
Akari Therapeutics Continues Key Research on its Novel ADC Payload PH1 to Demonstrate its Ability to Target Cancers Fueled by Oncogenic Drivers July 29, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases June 17, 2025
